ICP 488
Alternative Names: ICP-488Latest Information Update: 14 Oct 2024
Price :
$50 *
At a glance
- Originator InnoCare Pharma
- Class Anti-inflammatories; Antipsoriatics; Heterocyclic compounds; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Plaque psoriasis
- Preclinical Inflammatory bowel diseases; Systemic lupus erythematosus